Puma Biotechnology, Inc. (PBYI): Gross Profit
$170.21M
Year ended 2025-12-31
$173.04M
Trailing 12 months to 2026-06-30
-0.5%
3-year compound annual growth
-1.7%
5-year compound annual growth
| Period ended | Gross Profit | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $170.21M | +2.5% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $166.06M | -4.0% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $172.96M | 0.0% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $172.94M | -8.7% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $189.45M | +2.0% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $185.74M | -21.1% | 2023-03-02, From 2020-01-01 |
| 2019-12-31 | $235.44M | +8.8% | 2022-03-03, From 2019-01-01 |
| 2018-12-31 | $216.37M | +878.5% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $22.11M | n/a | 2020-02-28, From 2017-01-01 |
Gross Profit at similar companies
| Company | Year ended | Gross Profit | Change YoY |
|---|---|---|---|
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $170.21M | +2.5% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $196.73M | +102.8% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $120.87M | +48.5% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $142.61M | +8.0% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $127.10M | +150.3% |
| Harrow, Inc. (HROW) | 2025-12-31 | $204.37M | +35.9% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $170.26M | +45.8% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $33.99M | -68.6% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $141.61M | -22.9% |
Compare PBYI, AKBA, AMRN, SDGR side by side · Screen every company in Pharmaceutical Preparations ↗